Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug ...
The new results are from a phase 1 trial of a once-daily pill called CT-966 ... reach more than $125 billion in seven key markets by 2033.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback